Retinoic acid receptor agonists - Pipeline Insight, 2022

January 2022 | 60 pages | ID: R52B01101925EN
DelveInsight

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight’s, “Retinoic Acid Receptor (RARs) Agonist - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinoic Acid Receptor (RARs) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Retinoic Acid Receptor (RARs) Agonist Understanding

Retinoic Acid Receptor (RARs) Agonist: Overview

Retinoic acid receptors (RARs) are nuclear hormone receptors of the NR1B class, which function as heterodimers with retinoid X receptors (RXRs). The retinoic acid receptors (RAR?, RAR?, and RAR?) are members of the nuclear receptor superfamily. Compounds which bind to and activate the RARs are termed retinoids and comprise both natural retinol (Vitamin A) metabolites and synthetic analogs. Upon binding of an agonist ligands to RAR results in dissociation of corepressor and recruitment of coactivator protein that, promotes transcription of the downstream target gene into mRNA and eventually protein. Several Retinoic Acid Receptors (RAR) agonists have therapeutic activity against a variety of cancer types. RAR agonists presenting novel structural and chemical features could therefore open new avenues for the discovery of leads against breast, lung and prostate cancer or leukemia.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Retinoic Acid Receptor (RARs) Agonist R&D. The therapies under development are focused on novel approaches for Retinoic Acid Receptor (RARs) Agonist.

Retinoic Acid Receptor (RARs) Agonist Emerging Drugs Chapters

This segment of the Retinoic Acid Receptor (RARs) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Retinoic Acid Receptor (RARs) Agonist Emerging Drugs

• Palovarotene: Clementia Pharmaceuticals (Ipsen)

Palovarotene is a RAR? agonist being developed as a potential treatment for patients with ultra-rare and debilitating bone diseases, including fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), as well as other conditions including dry eye disease. Palovarotene had received rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder.

• IRX 5183: Allergan (AbbVie)

IRX 5183 is a selective, orally available, third generation vitamin A derivative and first in class Retinoic Acid Receptor alpha (RAR?) agonist. IRX 5183 is a drug that is designed to cause cancer cells to mature and then die. The drug is in Phase I/II clinical development for the treatment of cancer.

Further product details are provided in the report……..

Retinoic Acid Receptor (RARs) Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Retinoic Acid Receptor (RARs) Agonist drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Retinoic Acid Receptor (RARs) Agonist

There are approx. 15+ key companies which are developing the Retinoic Acid Receptor (RARs) Agonist. The companies which have their Retinoic Acid Receptor (RARs) Agonist drug candidates in the most advanced stage, i.e. Phase III include, Clementia Pharmaceuticals (Ipsen).

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Retinoic Acid Receptor (RARs) Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Retinoic Acid Receptor (RARs) Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Retinoic Acid Receptor (RARs) Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinoic Acid Receptor (RARs) Agonist drugs.

Retinoic Acid Receptor (RARs) Agonist Report Insights

• Retinoic Acid Receptor (RARs) Agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Retinoic Acid Receptor (RARs) Agonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Retinoic Acid Receptor (RARs) Agonist drugs?
• How many Retinoic Acid Receptor (RARs) Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Retinoic Acid Receptor (RARs) Agonist?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Retinoic Acid Receptor (RARs) Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Retinoic Acid Receptor (RARs) Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Clementia Pharmaceuticals (Ipsen)
• Nippon Shinyaku
• Bausch Health Companies
• Galderma
• Avecho Biotechnology
• Allergan (AbbVie)
• Celgene
• SciTech Development
• Polaryx Therapeutics

Key Products

• Palovarotene
• Tamibarotene
• IDP 126
• CD-5789
• Tretinoin topical
• IRX 5183
• Cintirorgon
• Fenretinide intravenous
• PLX-200

Contents

Introduction
Executive Summary
Retinoic Acid Receptor (RARs) Agonist: Overview
  Structure
  Mechanism of Action
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Retinoic Acid Receptor (RARs) Agonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  Retinoic Acid Receptor (RARs) Agonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Retinoic Acid Receptor (RARs) Agonist Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  Comparative Analysis
Palovarotene: Clementia Pharmaceuticals (Ipsen)
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
Tretinoin topical: Avecho Biotechnology
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
  Comparative Analysis
IRX 5183: Allergan (AbbVie)
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
  Comparative Analysis
Fenretinide intravenous: SciTech Development
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
Retinoic Acid Receptor (RARs) Agonist Key Companies
Retinoic Acid Receptor (RARs) Agonist Key Products
Retinoic Acid Receptor (RARs) Agonist- Unmet Needs
Retinoic Acid Receptor (RARs) Agonist- Market Drivers and Barriers
Retinoic Acid Receptor (RARs) Agonist- Future Perspectives and Conclusion
Retinoic Acid Receptor (RARs) Agonist Analyst Views
Retinoic Acid Receptor (RARs) Agonist Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Retinoic Acid Receptor (RARs) Agonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Retinoic Acid Receptor (RARs) Agonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products